title: Is it time for treat to target strategy in osteoporosis?
authors.affiliation: Inserm UMR 1033, université de Lyon, 69437 Lyon, France; Service de rhumatologie et de pathologie osseuse, hôpital E.-Herriot, 5, place d'Arsonval, 69437 Lyon, France. Electronic address: roland.chapurlat@inserm.fr.
authors.forename: Roland
authors.initials: R
authors.lastname: Chapurlat
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods; D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005598:Fractures, Spontaneous / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D017410:Practice Guidelines as Topic; D012015:Reference Standards; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents
keywords: Bisphosphonates; Bone mineral density; Denosumab; Fracture; Osteoporosis